A new antitumoral agent: 9-hydroxyellipticine. Possibility of a rational design of anticancerous drugs in the series of DNA intercalating drugs

  • Proc Natl Acad Sci U S A. 1974 Dec;71(12):5078-82. doi: 10.1073/pnas.71.12.5078.
J B Le Pecq ,  Nguyen-Dat-Xuong ,  C Gosse ,  C Paoletti
PMID: 4531039 DOI: 10.1073/pnas.71.12.5078
Abstract

The designing of DNA intercalating drugs with high DNA affinity in the series of ellipticine has led to a new antitumoral agent, 9-hydroxyellipticine, which has a high DNA affinity, a high activity on L 1210 mice leukemia, and a lack of toxicity at therapeutic dose. The possible correlations among chemical structure, DNA reactivity, and pharmacological activity of DNA intercalating drugs are discussed.

Products